Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Sharlene Litchy"'
Publikováno v:
Journal of Clinical Oncology. 24:3548-3554
Purpose To evaluate the efficacy of chemotherapy with paclitaxel, carboplatin, and etoposide in advanced adult poorly differentiated neuroendocrine carcinomas. Patients and Methods Patients eligible for this multicenter, phase II trial had metastatic
Autor:
Michel E. Kuzur, David R. Spigel, Kathleen Yost, Eric L. Raefsky, F. Anthony Greco, John D. Hainsworth, Sharlene Litchy, Kommor M
Publikováno v:
Cancer. 104:1992-1997
BACKGROUND The current study was performed to evaluate the activity of combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site. METHODS Patients with carcinoma of an unknown pr
Autor:
F. Anthony Greco, Lisa H. Morrissey, Matthew J. McCarty, Sharlene Litchy, Michael B. Andrews, John D. Hainsworth, Manuel Grimaldi
Publikováno v:
Journal of Clinical Oncology. 23:1500-1506
Purpose To evaluate the feasibility and efficacy of rituximab with short-duration chemotherapy in the first-line treatment of patients with follicular non-Hodgkin’s lymphoma (NHL). Patients and Methods Patients with previously untreated stage II-IV
Autor:
Van L. Lackey, F. Anthony Greco, John D. Hainsworth, Don W. Shaffer, Manuel Grimaldi, Sharlene Litchy
Publikováno v:
Journal of Clinical Oncology. 23:1088-1095
Purpose To compare the benefit of maintenance rituximab therapy versus rituximab re-treatment at progression in patients with previously treated indolent non-Hodgkin's lymphoma. Patients and Methods Between June 1998 and August 2002, 114 patients who
Autor:
F. Anthony Greco, James D. Bearden, Kathleen Yost, Sharlene Litchy, A. A. Meluch, John D. Hainsworth, Frederick M. Schnell
Publikováno v:
Cancer. 103:2298-2303
BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel, carboplatin, and gemcitabine in patients with advanced urothelial carcinoma. METHODS Patients with metastatic or loca
Autor:
Sharlene Litchy, John D. Hainsworth, J. R. Gray, F. Anthony Greco, Gerry Ann Houston, James D. Bearden, Don W. Shaffer
Publikováno v:
Clinical Lung Cancer. 6:33-42
This study was designed to evaluate the efficacy and toxicity of a novel preoperative combined-modality regimen in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with clinical stage IIB, IIIA, or IIIB NSCLC received preop
Autor:
F. Anthony Greco, Lisa H. Morrissey, Denise A. Yardley, Howard A. Burris, Steven W. Corso, Daniel C. Scullin, Sharlene Litchy, John D. Hainsworth
Publikováno v:
Journal of Clinical Oncology. 20:4261-4267
PURPOSE: To evaluate response to single-agent rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) and no previous systemic therapy, and the feasibility, toxicity, and efficacy of maintenance rituximab, administered at 6-month intervals
Autor:
Lisa H. Morrissey, John H. Barton, Sharlene Litchy, Daniel C. Scullin, John D. Hainsworth, Howard A. Burris, Joan B. Erland, Paul Richards, F. Anthony Greco, James E. Bradof
Publikováno v:
Journal of Clinical Oncology. 20:1651-1656
PURPOSE: To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site. PATIENTS AND METHODS: One hundred twenty
Autor:
Joan B. Erland, Lisa H. Morrissey, Steven W. Smith, F. Anthony Greco, David Rinaldi, Howard A. Burris, John D. Hainsworth, J. R. Gray, Charles Dobbs, Sharlene Litchy, Eric L. Raefsky
Publikováno v:
Cancer. 92:2142-2147
BACKGROUND The objective of this study was to determine the feasibility and toxicity of paclitaxel and carboplatin given in the adjuvant setting alone for patients with resected Stage IB disease and combined with radiotherapy for patients with resect
Autor:
Lisa H. Morrissey, John D. Hainsworth, Sharlene Litchy, John H. Barton, Howard A. Burris, James E. Bradof, F. Anthony Greco
Publikováno v:
Cancer. 89:328-333
BACKGROUND Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors evaluated the feasibility, toxicity, an